{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:40:10Z","timestamp":1790505610791,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,6,13]],"date-time":"2017-06-13T00:00:00Z","timestamp":1497312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,6,13]],"date-time":"2017-06-13T00:00:00Z","timestamp":1497312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Idiopathic pulmonary fibrosis (IPF) involves alveolar epithelial injury and abnormal collagen production caused by activated fibroblasts; transforming growth factor (TGF)-\u03b21 is implicated in this activation. In this study, we screened for chemicals capable of inhibiting TGF-\u03b21-induced collagen production in cultured fibroblasts from medicines already in clinical use. We selected felodipine based on its extent of collagen production inhibition, clinical safety profile, and other pharmacological activity. Felodipine is a dihydropyridine Ca\n                    <jats:sup>2+<\/jats:sup>\n                    channel blocker that has been used clinically to treat patients with high blood pressure. Felodipine suppressed collagen production within LL29 cells in the presence of TGF-\u03b21, but not in its absence. Intratracheal administration of felodipine prevented bleomycin-induced pulmonary fibrosis, alteration of lung mechanics and respiratory dysfunction. Felodipine also improved pulmonary fibrosis, as well as lung and respiratory function when administered after fibrosis development. Furthermore, administration of felodipine suppressed a bleomycin-induced increase in activated fibroblasts in the lung. We also found other dihydropyridine Ca\n                    <jats:sup>2+<\/jats:sup>\n                    channel blockers (nifedipine and benidipine) inhibited collagen production\n                    <jats:italic>in vitro<\/jats:italic>\n                    and partially prevented bleomycin-induced pulmonary fibrosis, alteration of lung mechanics and respiratory dysfunction\n                    <jats:italic>in vivo<\/jats:italic>\n                    . We propose that these Ca\n                    <jats:sup>2+<\/jats:sup>\n                    channel blockers may be therapeutically beneficial for IPF patients.\n                  <\/jats:p>","DOI":"10.1038\/s41598-017-03676-y","type":"journal-article","created":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T10:44:39Z","timestamp":1496832279000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Protective and therapeutic effect of felodipine against bleomycin-induced pulmonary fibrosis in mice"],"prefix":"10.1038","volume":"7","author":[{"given":"Ken-ichiro","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Niino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Takafuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Sugizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiya","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Kurotsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kawahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Mizushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,13]]},"reference":[{"key":"3676_CR1","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1513\/pats.200601-005TK","volume":"3","author":"DS Kim","year":"2006","unstructured":"Kim, D. S., Collard, H. R. & King, T. E. Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 3, 285\u2013292 (2006).","journal-title":"Proc Am Thorac Soc"},{"key":"3676_CR2","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","volume":"192","author":"G Raghu","year":"2015","unstructured":"Raghu, G. et al. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med 192, e3\u201319, doi:10.1164\/rccm.201506-1063ST (2015).","journal-title":"Am J Respir Crit Care Med"},{"key":"3676_CR3","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.rmed.2004.07.019","volume":"98","author":"F Luppi","year":"2004","unstructured":"Luppi, F., Cerri, S., Beghe, B., Fabbri, L. M. & Richeldi, L. Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis. Respir Med 98, 1035\u20131044 (2004).","journal-title":"Respir Med"},{"key":"3676_CR4","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1513\/pats.200602-016TK","volume":"3","author":"N Walter","year":"2006","unstructured":"Walter, N., Collard, H. R. & King, T. E. Jr. Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc Am Thorac Soc 3, 330\u2013338 (2006).","journal-title":"Proc Am Thorac Soc"},{"key":"3676_CR5","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","volume":"377","author":"PW Noble","year":"2011","unstructured":"Noble, P. W. et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377, 1760\u20131769, doi:10.1016\/S0140-6736(11)60405-4 (2011).","journal-title":"Lancet"},{"key":"3676_CR6","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi, L. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370, 2071\u20132082, doi:10.1056\/NEJMoa1402584 (2014).","journal-title":"N Engl J Med"},{"key":"3676_CR7","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1089\/ars.2007.1942","volume":"10","author":"VL Kinnula","year":"2008","unstructured":"Kinnula, V. L. & Myllarniemi, M. Oxidant-antioxidant imbalance as a potential contributor to the progression of human pulmonary fibrosis. Antioxid Redox Signal 10, 727\u2013738 (2008).","journal-title":"Antioxid Redox Signal"},{"key":"3676_CR8","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1513\/pats.200601-008AW","volume":"3","author":"D Sheppard","year":"2006","unstructured":"Sheppard, D. Transforming growth factor beta: a central modulator of pulmonary and airway inflammation and fibrosis. Proc Am Thorac Soc 3, 413\u2013417, doi:10.1513\/pats.200601-008AW (2006).","journal-title":"Proc Am Thorac Soc"},{"key":"3676_CR9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1089\/ars.2007.1912","volume":"10","author":"VL Kinnula","year":"2008","unstructured":"Kinnula, V. L. Redox imbalance and lung fibrosis. Antioxid Redox Signal 10, 249\u2013252, doi:10.1089\/ars.2007.1912 (2008).","journal-title":"Antioxid Redox Signal"},{"key":"3676_CR10","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.2353\/ajpath.2007.070112","volume":"170","author":"B Hinz","year":"2007","unstructured":"Hinz, B. et al. The myofibroblast: one function, multiple origins. Am J Pathol 170, 1807\u20131816 (2007).","journal-title":"Am J Pathol"},{"key":"3676_CR11","doi-asserted-by":"publisher","first-page":"L525","DOI":"10.1152\/ajplung.00163.2007","volume":"293","author":"BC Willis","year":"2007","unstructured":"Willis, B. C. & Borok, Z. TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol 293, L525\u2013534 (2007).","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"3676_CR12","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1378\/chest.09-0510","volume":"136","author":"RM Strieter","year":"2009","unstructured":"Strieter, R. M. & Mehrad, B. New mechanisms of pulmonary fibrosis. Chest 136, 1364\u20131370, doi:10.1378\/chest.09-0510 (2009).","journal-title":"Chest"},{"key":"3676_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ejps.2014.02.014","volume":"58","author":"E Conte","year":"2014","unstructured":"Conte, E. et al. Effect of pirfenidone on proliferation, TGF-beta-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci 58, 13\u201319, doi:10.1016\/j.ejps.2014.02.014 (2014).","journal-title":"Eur J Pharm Sci"},{"key":"3676_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1471-2466-12-24","volume":"12","author":"K Hisatomi","year":"2012","unstructured":"Hisatomi, K. et al. Pirfenidone inhibits TGF-beta1-induced over-expression of collagen type I and heat shock protein 47 in A549 cells. BMC Pulm Med 12, 24, doi:10.1186\/1471-2466-12-24 (2012).","journal-title":"BMC Pulm Med"},{"key":"3676_CR15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1124\/jpet.113.208223","volume":"349","author":"L Wollin","year":"2014","unstructured":"Wollin, L., Maillet, I., Quesniaux, V., Holweg, A. & Ryffel, B. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther 349, 209\u2013220, doi:10.1124\/jpet.113.208223 (2014).","journal-title":"J Pharmacol Exp Ther"},{"key":"3676_CR16","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/jb\/mvr032","volume":"149","author":"T Mizushima","year":"2011","unstructured":"Mizushima, T. Drug discovery and development focusing on existing medicines: drug re-profiling strategy. J Biochem 149, 499\u2013505, doi:10.1093\/jb\/mvr032 (2011).","journal-title":"J Biochem"},{"key":"3676_CR17","doi-asserted-by":"publisher","first-page":"4510","DOI":"10.1038\/srep04510","volume":"4","author":"K Tanaka","year":"2014","unstructured":"Tanaka, K. et al. Superiority of pulmonary administration of mepenzolate bromide over other routes as treatment for chronic obstructive pulmonary disease. Scientific reports 4, 4510, doi:10.1038\/srep04510 (2014).","journal-title":"Scientific reports"},{"key":"3676_CR18","doi-asserted-by":"publisher","unstructured":"Tanaka, K. et al. Mepenzolate bromide displays beneficial effects in a mouse model of chronic obstructive pulmonary disease. Nat Commun 4, doi:10.1038\/ncomms3686 (2013).","DOI":"10.1038\/ncomms3686"},{"key":"3676_CR19","doi-asserted-by":"publisher","first-page":"17519","DOI":"10.1038\/srep17519","volume":"5","author":"T Asano","year":"2015","unstructured":"Asano, T. et al. Aldioxa improves delayed gastric emptying and impaired gastric compliance, pathophysiologic mechanisms of functional dyspepsia. Scientific reports 5, 17519, doi:10.1038\/srep17519 (2015).","journal-title":"Scientific reports"},{"key":"3676_CR20","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/BF01857641","volume":"4","author":"R Larsson","year":"1990","unstructured":"Larsson, R. et al. Felodipine in the treatment of patients with severe hypertension and impaired renal function. Cardiovasc Drugs Ther 4, 253\u2013259 (1990).","journal-title":"Cardiovasc Drugs Ther"},{"key":"3676_CR21","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1513\/pats.200605-125SF","volume":"3","author":"J Gauldie","year":"2006","unstructured":"Gauldie, J. et al. Smad3 signaling involved in pulmonary fibrosis and emphysema. Proc Am Thorac Soc 3, 696\u2013702, doi:10.1513\/pats.200605-125SF (2006).","journal-title":"Proc Am Thorac Soc"},{"key":"3676_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00441-011-1201-y","volume":"347","author":"Y Mu","year":"2012","unstructured":"Mu, Y., Gudey, S. K. & Landstrom, M. Non-Smad signaling pathways. Cell Tissue Res 347, 11\u201320, doi:10.1007\/s00441-011-1201-y (2012).","journal-title":"Cell Tissue Res"},{"key":"3676_CR23","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1378\/chest.11-2879","volume":"142","author":"K Tanaka","year":"2012","unstructured":"Tanaka, K., Azuma, A., Miyazaki, Y., Sato, K. & Mizushima, T. Effects of lecithinized superoxide dismutase and\/or pirfenidone against bleomycin-induced pulmonary fibrosis. Chest 142, 1011\u20131019, doi:10.1378\/chest.11-2879 (2012).","journal-title":"Chest"},{"key":"3676_CR24","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.bcp.2010.05.025","volume":"80","author":"K Tanaka","year":"2010","unstructured":"Tanaka, K., Tanaka, Y., Namba, T., Azuma, A. & Mizushima, T. Heat shock protein 70 protects against bleomycin-induced pulmonary fibrosis in mice. Biochem Pharmacol 80, 920\u2013931, doi:10.1016\/j.bcp.2010.05.025 (2010).","journal-title":"Biochem Pharmacol"},{"key":"3676_CR25","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1378\/chest.06-2568","volume":"132","author":"CJ Scotton","year":"2007","unstructured":"Scotton, C. J. & Chambers, R. C. Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest 132, 1311\u20131321, doi:10.1378\/chest.06-2568 (2007).","journal-title":"Chest"},{"key":"3676_CR26","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1165\/rcmb.2015-0009OC","volume":"53","author":"S Mukherjee","year":"2015","unstructured":"Mukherjee, S. et al. Disruption of Calcium Signaling in Fibroblasts and Attenuation of Bleomycin-Induced Fibrosis by Nifedipine. Am J Respir Cell Mol Biol 53, 450\u2013458, doi:10.1165\/rcmb.2015-0009OC (2015).","journal-title":"Am J Respir Cell Mol Biol"},{"key":"3676_CR27","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1165\/rcmb.2011-0223OC","volume":"46","author":"S Mukherjee","year":"2012","unstructured":"Mukherjee, S., Kolb, M. R., Duan, F. & Janssen, L. J. Transforming growth factor-beta evokes Ca2+ waves and enhances gene expression in human pulmonary fibroblasts. Am J Respir Cell Mol Biol 46, 757\u2013764, doi:10.1165\/rcmb.2011-0223OC (2012).","journal-title":"Am J Respir Cell Mol Biol"},{"key":"3676_CR28","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0022-3565(25)21510-5","volume":"226","author":"JD Johnson","year":"1983","unstructured":"Johnson, J. D. & Fugman, D. A. Calcium and calmodulin antagonists binding to calmodulin and relaxation of coronary segments. J Pharmacol Exp Ther 226, 330\u2013334 (1983).","journal-title":"J Pharmacol Exp Ther"},{"key":"3676_CR29","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.neuron.2011.02.051","volume":"70","author":"J Vriens","year":"2011","unstructured":"Vriens, J. et al. TRPM3 is a nociceptor channel involved in the detection of noxious heat. Neuron 70, 482\u2013494, doi:10.1016\/j.neuron.2011.02.051 (2011).","journal-title":"Neuron"},{"key":"3676_CR30","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1183\/09031936.04.00120803","volume":"24","author":"T Kakugawa","year":"2004","unstructured":"Kakugawa, T. et al. Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis. Eur Respir J 24, 57\u201365 (2004).","journal-title":"Eur Respir J"},{"key":"3676_CR31","doi-asserted-by":"publisher","first-page":"L152","DOI":"10.1152\/ajplung.00313.2007","volume":"294","author":"BB Moore","year":"2008","unstructured":"Moore, B. B. & Hogaboam, C. M. Murine models of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 294, L152\u2013160 (2008).","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"3676_CR32","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1007\/s10753-016-0396-1","volume":"39","author":"W Wang","year":"2016","unstructured":"Wang, W. et al. Chronic Calcium Channel Inhibitor Verapamil Antagonizes TNF-alpha-Mediated Inflammatory Reaction and Protects Against Inflammatory Arthritis in Mice. Inflammation 39, 1624\u20131634, doi:10.1007\/s10753-016-0396-1 (2016).","journal-title":"Inflammation"},{"key":"3676_CR33","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1111\/j.1745-7254.2008.00843.x","volume":"29","author":"HW Tan","year":"2008","unstructured":"Tan, H. W. et al. Felodipine attenuates vascular inflammation in a fructose-induced rat model of metabolic syndrome via the inhibition of NF-kappaB activation. Acta Pharmacol Sin 29, 1051\u20131059, doi:10.1111\/j.1745-7254.2008.00843.x (2008).","journal-title":"Acta Pharmacol Sin"},{"key":"3676_CR34","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/j.rmed.2014.08.008","volume":"108","author":"M Al-Alawi","year":"2014","unstructured":"Al-Alawi, M., Hassan, T. & Chotirmall, S. H. Transforming growth factor beta and severe asthma: a perfect storm. Respir Med 108, 1409\u20131423, doi:10.1016\/j.rmed.2014.08.008 (2014).","journal-title":"Respir Med"},{"key":"3676_CR35","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1378\/chest.08-1341","volume":"134","author":"RJ Davies","year":"2008","unstructured":"Davies, R. J. & Morrell, N. W. Molecular mechanisms of pulmonary arterial hypertension: role of mutations in the bone morphogenetic protein type II receptor. Chest 134, 1271\u20131277, doi:10.1378\/chest.08-1341 (2008).","journal-title":"Chest"},{"key":"3676_CR36","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1165\/rcmb.2014-0282RT","volume":"52","author":"FM Verhamme","year":"2015","unstructured":"Verhamme, F. M., Bracke, K. R., Joos, G. F. & Brusselle, G. G. Transforming growth factor-beta superfamily in obstructive lung diseases. more suspects than TGF-beta alone. Am J Respir Cell Mol Biol 52, 653\u2013662, doi:10.1165\/rcmb.2014-0282RT (2015).","journal-title":"Am J Respir Cell Mol Biol"},{"key":"3676_CR37","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1164\/rccm.201410-1874OC","volume":"191","author":"PO Girodet","year":"2015","unstructured":"Girodet, P. O. et al. Calcium channel blocker reduces airway remodeling in severe asthma. A proof-of-concept study. Am J Respir Crit Care Med 191, 876\u2013883, doi:10.1164\/rccm.201410-1874OC (2015).","journal-title":"Am J Respir Crit Care Med"},{"key":"3676_CR38","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1167\/iovs.13-13850","volume":"55","author":"R Sawazaki","year":"2014","unstructured":"Sawazaki, R. et al. Diclofenac protects cultured human corneal epithelial cells against hyperosmolarity and ameliorates corneal surface damage in a rat model of dry eye. Invest Ophthalmol Vis Sci 55, 2547\u20132556, doi:10.1167\/iovs.13-13850 (2014).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3676_CR39","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/0003-9861(61)90291-0","volume":"93","author":"JF Woessner Jr.","year":"1961","unstructured":"Woessner, J. F. Jr. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys 93, 440\u2013447 (1961).","journal-title":"Arch Biochem Biophys"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-03676-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-03676-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-03676-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T20:58:44Z","timestamp":1750280324000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-03676-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,13]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["3676"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-03676-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,13]]},"assertion":[{"value":"8 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"3439"}}